Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer Therapy
Zachary B. Jenner, Anil K. Sood, Robert L. Coleman
Future Oncology (2016) Vol. 12, Iss. 12, pp. 1439-1456
Open Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, et al.
Medicines (2020) Vol. 7, Iss. 9, pp. 54-54
Open Access | Times Cited: 28
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
Ying Chen, Hui Du
Biomedicine & Pharmacotherapy (2018) Vol. 99, pp. 552-560
Closed Access | Times Cited: 31
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
Laurence Booth, Jane L. Roberts, Peter Samuel, et al.
Cancer Biology & Therapy (2018) Vol. 19, Iss. 6, pp. 525-533
Open Access | Times Cited: 29
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Z. Ping Lin, Yong-Lian Zhu, Ying‐Chun Lo, et al.
PLoS ONE (2018) Vol. 13, Iss. 11, pp. e0207399-e0207399
Open Access | Times Cited: 29
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Graziela Zibetti Dal Molin, Kohei Omatsu, Anil K. Sood, et al.
Therapeutic Advances in Medical Oncology (2018) Vol. 10
Open Access | Times Cited: 28
Synthesis of C4-Substituted Indoles via a Catellani and C–N Bond Activation Strategy
Bo‐Sheng Zhang, Fan Wang, Ying-Hui Yang, et al.
Organic Letters (2020) Vol. 22, Iss. 21, pp. 8267-8271
Closed Access | Times Cited: 27
Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer
Jingyi Zhang, Lijie Zhao, Yatao Wang
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115925-115925
Closed Access | Times Cited: 8
Ovarian Cancer Genetics: Subtypes and Risk Factors
Jeff Hirst, Jennifer Crow, Andrew K. Godwin
InTech eBooks (2018)
Open Access | Times Cited: 24
PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer
Adam Kraya, Kara N. Maxwell, Monika A. Eiva, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 12
Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Ling Yu, Zhiwei Yan, Youde Wang, et al.
Medicinal Chemistry Research (2022) Vol. 31, Iss. 8, pp. 1265-1276
Closed Access | Times Cited: 12
Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
Jim Xiao, Dorota Nowak, Rodryg Ramlau, et al.
Clinical and Translational Science (2018) Vol. 12, Iss. 1, pp. 58-65
Open Access | Times Cited: 19
Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer
Kelly McCann
Current Opinion in Obstetrics & Gynecology (2017) Vol. 30, Iss. 1, pp. 7-16
Closed Access | Times Cited: 17
Investigation of the Adsorption Rubraca Anticancer Drug on the CNT(4,4-8) Nanotube as a Factor of Drug Delivery: A Theoretical Study Based on DFT Method
Masoome Sheikhi, Siyamak Shаhаb, Mehrnoosh Khaleghian, et al.
Current Molecular Medicine (2019) Vol. 19, Iss. 7, pp. 473-486
Closed Access | Times Cited: 16
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
Mingxiang Liao, Jeri Beltman, Heidi Giordano, et al.
Clinical Pharmacokinetics (2022) Vol. 61, Iss. 11, pp. 1477-1493
Open Access | Times Cited: 9
Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer
Xin Wu, Qiong Wang, Peifa Liu, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 9
Novel Chemotherapy Modalities for Different Cancers
Divya V Lohiya, Ashok M Mehendale, Drishti V Lohiya, et al.
Cureus (2023)
Open Access | Times Cited: 5
Novel Therapeutics for Ovarian Cancer
Neil Johnson, John B. Liao
International Journal of Gynecological Cancer (2017) Vol. 27, pp. S14-S19
Closed Access | Times Cited: 16
DNA Double Strand Break Repair - Related Synthetic Lethality
Monika M. Toma, Tomasz Skórski, Tomasz Śliwiński
Current Medicinal Chemistry (2018) Vol. 26, Iss. 8, pp. 1446-1482
Closed Access | Times Cited: 13
Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus
Ettore Capoluongo, Giovanni Scambia, Jean‐Marc Nabholtz
Oncotarget (2018) Vol. 9, Iss. 28, pp. 19463-19468
Open Access | Times Cited: 13
Determination of the DNA binding properties of a novel PARP inhibitor MK-4827 with calf-thymus DNA by molecular simulations and detailed spectroscopic investigations
Hongqin Yang, Qingle Zeng, Ze He, et al.
New Journal of Chemistry (2019) Vol. 43, Iss. 17, pp. 6702-6711
Closed Access | Times Cited: 13
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression
Jonathan Krell, Danielle Shaw, John McGrane, et al.
Future Oncology (2024), pp. 1-11
Open Access | Times Cited: 1
AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China
Jiani Pan, Pu‐Chun Li, Meng Wang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Rucaparib in Ovarian Cancer: Extending the Use of PARP Inhibitors in the Recurrent Disease
Graziela Zibetti Dal Molin, Shannon N. Westin, Robert L. Coleman
Future Oncology (2018) Vol. 14, Iss. 30, pp. 3101-3110
Open Access | Times Cited: 11
PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Prashant Mehta, Sneha Bothra
Advances in genetics (2021), pp. 35-80
Closed Access | Times Cited: 8
Exploring the structural and functional requirements of Phyto-compounds and their synthetic scaffolds as anticancer agents: Medicinal chemistry perspective
Dipanjan Karati, Dileep Kumar
Pharmacological Research - Modern Chinese Medicine (2022) Vol. 4, pp. 100123-100123
Open Access | Times Cited: 6

Scroll to top